Mario Alvares-da-Silva

Nov 13, 2023 | nejm.org | Kris V. Kowdley |Christopher L. Bowlus |Cynthia Levy |Mario Alvares-da-Silva

November 13, 2023 DOI: 10.1056/NEJMoa2306185 AbstractPrimary biliary cholangitis is a rare, chronic cholestatic liver disease characterized by the destruction of interlobular bile ducts, leading to cholestasis and liver fibrosis. Whether elafibranor, an oral, dual peroxisome proliferator-activated receptor (PPAR) α and δ agonist, may have benefit as a treatment for primary biliary cholangitis is unknown.

Nov 13, 2023 | nejm.org | Kris V. Kowdley |Christopher L. Bowlus |Cynthia Levy |Mario Alvares-da-Silva

AbstractPrimary biliary cholangitis is a rare, chronic cholestatic liver disease characterized by the destruction of interlobular bile ducts, leading to cholestasis and liver fibrosis. Whether elafibranor, an oral, dual peroxisome proliferator-activated receptor (PPAR) α and δ agonist, may have benefit as a treatment for primary biliary cholangitis is unknown.